{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:47:58Z","timestamp":1767829678422,"version":"3.49.0"},"reference-count":34,"publisher":"Informa UK Limited","issue":"12","funder":[{"name":"no funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2021,12,2]]},"DOI":"10.1080\/14737140.2021.1988853","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T02:01:21Z","timestamp":1633140081000},"page":"1313-1320","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma"],"prefix":"10.1080","volume":"21","author":[{"given":"Nausheen","family":"Ahmed","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancy and Cellular Therapeutics, University of Kansas, Kansas City, KS, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,10,17]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.06.036"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007939"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009782"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2017.1366447"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0474-2"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-019-0178-7"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.573477"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007512"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0711"},{"issue":"1","key":"cit0019","first-page":"1321","volume":"130","author":"Jain N","year":"2017","journal-title":"Blood"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-813493"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28533-4"},{"key":"cit0022","doi-asserted-by":"crossref","unstructured":"Caimi P, Ai W, Alderuccio JP, et al. Duration of response to loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: subgroup analyses from LOTIS 2. Wolters Kluwer Health; 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.7546"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136614"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7574"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.771"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018027748"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e18562"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114152"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"cit0030","unstructured":"Phase III study shows Roche\u2019s Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care. [Internet]. News Release;Roche;2020 [cited 2021 Aug 9];https:\/\/bit.ly\/3CwmRLe"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002587"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134449"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2021.1988853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:48:49Z","timestamp":1637045329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2021.1988853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,17]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,2]]}},"alternative-id":["10.1080\/14737140.2021.1988853"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2021.1988853","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}